Autoimmune disease Archives

autoimmune disease enzyme hansa medical 1

News and Trends 19 Feb 2018

The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease

The FDA has awarded Hansa Medical’s lead candidate for the treatment of an autoimmune disease with Orphan Drug Designation, which will support its journey through clinical development. Swedish biotech, Hansa Medical, develops enzymes that can help to control the immune system for transplantations and the treatment of autoimmune diseases. The company’s lead candidate, IdeS, has […]

February 19, 2018 - 2 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?

Two clinical studies have demonstrated the capacity of Novartis’ monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T cell therapy field with the approval of Kymriah last year, the big pharma is also developing drugs for diseases affecting the immune system. The company presented […]

February 19, 2018 - 3 minutesmins - By Alex Dale

News and Trends 19 Feb 2018

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […]

February 19, 2018 - 3 minutesmins - By Alex Dale

Interview 19 Feb 2018

Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease

CAR-T cells are all the rage as the latest treatment for cancer. But what if we could apply this same technology to treat autoimmune disease? Curious to learn whether this new technology could revolutionize yet another field of medicine, I talked to Stephane Boissel, CEO of TxCell, to discuss the future of the field and his […]

February 19, 2018 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Jan 2018

Your Pee Could Be Used to Build an Artificial Adrenal Gland

Scientists have started generating artificial glands using cells derived from urine, which will allow the study of adrenal disorders that affect growth, development, and metabolism. Researchers at Queen Mary University of London have used cells in urine to begin generating an artificial adrenal gland that could be used to treat adrenal gland disorders. The study, published in Cell Reports, […]

January 31, 2018 - 3 minutesmins - By Alex Dale

autoimmune diseases psoriasis arthritis 1

News and Trends 18 Jan 2018

This Cytokine is Key to Autoimmune and Inflammatory Diseases

An international group of researchers has found that the cytokine IL-23 is heavily involved in autoimmune and inflammatory diseases, opening the door to new therapies targeting the molecule. Research at the VIB-UGent Center for Inflammation Research has identified a crucial molecular mechanism underlying autoimmune and inflammatory diseases like psoriasis, rheumatoid arthritis, and multiple sclerosis. The study, […]

January 18, 2018 - 3 minutesmins - By Alex Dale

News and Trends 11 Dec 2017

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

A Phase II proof of concept study has shown that one of Argenx’ antibodies is effective in treating the neuromuscular disease myasthenia gravis. Argenx has released the results from a Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease […]

December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 21 Nov 2017

German Biotech Reels in €34M for its Cancer-Killing Technology

Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the toxin, Amanitin. Heidelberg Pharma has attracted over €34M of investment to support the development of its Antibody Targeted Amanitin Conjugates (ATACs) technology. The biotech, formerly Wilex, is developing drugs for cancer and autoimmune diseases, with the hope that the addition of Amanitin to antibody-drug conjugate (ADC) technology could produce […]

November 21, 2017 - 1 minutemin - By Alex Dale

News and Trends 21 Nov 2017

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Step Pharma will use the proceeds of its first fundraising round to support the development of immunomodulators for autoimmune diseases towards the clinic. Step Pharma develops inhibitors targeting an enzyme called cytidine nucleotide triphosphate (CTPS1) for the treatment of a range of autoimmune diseases. The company is working on several candidates, the most advanced of which […]

November 21, 2017 - 3 minutesmins - By Alex Dale

imcyse type 1 diabetes immunotherapy cure

News and Trends 15 Nov 2017

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

Update (15/11/2017): Imcyse has officially started recruiting patients to test its therapy for type 1 diabetes. The clinical trial will recruit up to 40 patients across 15 European centers, and the first patient has already enrolled at the Steno Diabetes Center in Copenhagen. Originally published on 30/05/2017 Imcyse will run its first clinical trial testing […]

November 15, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Topas Therapeutics received an extra €4M from Boehringer Ingelheim Venture Fund to help its autoimmune disease candidates accelerated through trials. Hamburg-based Topas Therapeutics, a spin-off from Evotec, develops products for autoimmune diseases with high medical need. With the announcement of a €18M Series A, it hopes to take begin moving its candidates into the clinic. It had raised €14M thanks to investment from Epidarex […]

November 2, 2017 - 2 minutesmins - By Alex Dale

News and Trends 1 Nov 2017

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Apitope develops highly specific peptide therapeutics for multiple sclerosis and other autoimmune diseases, and will now launch an IPO on Brussels Euronext. Apitope hopes to treat a number of autoimmune diseases affecting many systems throughout the body. The company has developed peptides, ‘apitopes‘, that tackle the immunological basis of the disease. The company has just […]

November 1, 2017 - 2 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Autoimmune disease

The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease

Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown?

This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline

Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease

Your Pee Could Be Used to Build an Artificial Adrenal Gland

This Cytokine is Key to Autoimmune and Inflammatory Diseases

Belgian Antibody Proves Effective to Treat Myasthenia Gravis

German Biotech Reels in €34M for its Cancer-Killing Technology

French Biotech Steps Up Autoimmune Disease Drug Development with €14.5M Series A

Update: Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure

German Biotech Pockets €18M in its Series A to Propel Autoimmune Disease Candidate Forward

Belgian Biotech Launches IPO, Readying Itself to Fight Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!